全文获取类型
收费全文 | 642篇 |
免费 | 83篇 |
国内免费 | 13篇 |
专业分类
儿科学 | 1篇 |
妇产科学 | 4篇 |
基础医学 | 38篇 |
口腔科学 | 7篇 |
临床医学 | 118篇 |
内科学 | 224篇 |
皮肤病学 | 2篇 |
神经病学 | 55篇 |
特种医学 | 3篇 |
外科学 | 58篇 |
综合类 | 35篇 |
现状与发展 | 1篇 |
预防医学 | 19篇 |
眼科学 | 5篇 |
药学 | 138篇 |
中国医学 | 5篇 |
肿瘤学 | 25篇 |
出版年
2024年 | 5篇 |
2023年 | 17篇 |
2022年 | 16篇 |
2021年 | 26篇 |
2020年 | 33篇 |
2019年 | 28篇 |
2018年 | 50篇 |
2017年 | 31篇 |
2016年 | 36篇 |
2015年 | 46篇 |
2014年 | 44篇 |
2013年 | 106篇 |
2012年 | 36篇 |
2011年 | 41篇 |
2010年 | 31篇 |
2009年 | 42篇 |
2008年 | 31篇 |
2007年 | 28篇 |
2006年 | 20篇 |
2005年 | 25篇 |
2004年 | 19篇 |
2003年 | 9篇 |
2002年 | 6篇 |
2001年 | 3篇 |
2000年 | 3篇 |
1999年 | 2篇 |
1997年 | 1篇 |
1995年 | 1篇 |
1990年 | 1篇 |
1989年 | 1篇 |
排序方式: 共有738条查询结果,搜索用时 31 毫秒
1.
4-(4-氟苯基)-6-异丙基-2-(N-甲基-N-甲磺酰胺基)嘧啶-5-羧酸甲酯的合成 总被引:1,自引:0,他引:1
目的 合成罗苏伐他汀的关键中间体4-(4-氟苯基)-6-异丙基-2-(N-甲基-N-甲磺酰胺基)嘧啶-5-羧酸甲酯。方法 以异丁酰乙酸甲酯为起始原料,经与对氟苯甲醛缩合、S-甲基异硫脲硫酸盐环合、高锰酸钾氧化,再经甲胺基、甲磺酰基取代全盛的目标化合物。结果 5步反应总收率为25.0%。结论 改进了合成路线,有助于罗苏伐他汀的合成。 相似文献
2.
3.
4.
《Clinical and experimental hypertension (New York, N.Y. : 1993)》2013,35(8):698-704
We have demonstrated that oxidative stress in the rostral ventrolateral medulla (RVLM), a vasomotor center in brainstem, increases sympathetic nerve activity (SNA) and that oral administration of atorvastatin inhibited SNA via anti-oxidant effect in the RVLM of stroke-prone spontaneously hypertensive rats (SHRSPs). The impairment of baroreflex sensitivity (BRS) is known as the predictive factor of mortality in the hypertension and BRS is impaired in SHRSP. The aim of the present study was to determine whether oral administration of atorvastatin improved the impaired BRS via anti-oxidant effect in the RVLM in SHRSP. Atorvastatin (20 mg/kg/day) or vehicle was orally administered for 28 days in SHRSPs. Systolic blood pressure (SBP), heart rate, and 24-h urinary norepinephrine excretion as an indicator of SNA were comparable between atorvastatin- and control-SHRSP. Thiobarbituric acid-reactive substance (TBARS) levels as a marker of oxidative stress was significantly lower in atorvastatin-SHRSP than in control-SHRSP. Baroreflex sensitivity measured by the spontaneous sequence method was significantly higher in atorvastatin-SHRSP than in control-SHRSP. These results suggest that atorvastatin improves the impaired BRS in SHRSP via its anti-oxidant effect in the RVLM of SHRSP. 相似文献
5.
Analysis and comparison of statin prescription patterns and outcomes according to clinical department
下载免费PDF全文
![点击此处可从《Journal of clinical pharmacy and therapeutics》网站下载免费的PDF全文](/ch/ext_images/free.gif)
6.
7.
Statin-induced necrotizing autoimmune myopathy (SINAM) is associated with a unique clinical 5 phenotype of severe proximal muscle weakness during or after exposure to statins in patients with high creatine kinase (CK) levels. Electromyography (EMG) and muscle biopsy reveal features of a necrotizing myopathy and the anti-HMGCR autoantibody is frequently detected. Treatment requires a combination of statin discontinuation as well as immunomodulatory or immunosuppressive therapy. HLA typing (HLADRB1*1101) is strongly associated with anti-10 HMGCR autoantibody positivity in statin-exposed patients. It is well documented that statin triggers autoimmune disease in those with a genetic susceptibility. With the commercial availability of an accurate ELISA test, the natural history of the disease and its phenotypic features are becoming increasingly understood. 相似文献
8.
《Expert opinion on pharmacotherapy》2013,14(5):819-830
Atorvastatin (Lipitor?, Pfizer) is a safe and effective 3-hydroxy-3-methyl-glutaryl-CoA (HMG-CoA) reductase inhibitor (statin). It is the most potent currently available statin in terms of lowering low-density lipoprotein (LDL) and total cholesterol levels. It was the first statin shown to lower triglycerides in patients with isolated hypertriglyceridaemia. It has a good safety profile. In common with other statins, it has non-lipid-lowering effects including improving endothelial function, antiproliferative actions on smooth muscle and reducing platelet aggregation. It also has anti-inflammatory effects and may reduce plasma glucose levels. Clinical trial evidence with this statin is currently limited. It did slightly reduce events in the AVERT trial comparing patients receiving coronary angioplasty with those receiving high-dose atorvastatin therapy and in the MIRACL study reduced ischemia in patients with acute coronary syndromes. Other end point trials are in progress. 相似文献
9.
10.
Evolocumab and lipoprotein apheresis combination therapy may have synergic effects to reduce low‐density lipoprotein cholesterol levels in heterozygous familial hypercholesterolemia: A case report
下载免费PDF全文
![点击此处可从《Journal of clinical apheresis》网站下载免费的PDF全文](/ch/ext_images/free.gif)
M. G. Zenti C. Stefanutti V. Sanga A. Altomari A. Fabris M. Dauriz E. Bonora 《Journal of clinical apheresis》2018,33(4):546-550
A 49 years old woman (weight 68 kg, BMI 27.3 kg/m2) with heterozygous familial hypercholesterolemia (HeFH) and multiple statin intolerance with muscle aches and creatine kinase elevation, presented at the Outpatient Lipid Clinic of Verona University Hospital in May 2015. Hypercholesterolemia was firstly diagnosed during adolescence, followed in adulthood by a diagnosis of Cogan's syndrome, a rheumatologic disorder characterized by corneal and inner ear inflammation. No xanthomas, corneal arcus, or vascular bruits were detectable at physical examination. Screening for macrovascular complications did not reveal relevant damages. Ongoing medical therapy included salicylic acid, methylprednisolone, methotrexate, and protonic‐pump inhibitor. In the absence of specific lipid‐lowering therapy, plasma lipid levels at first visit were: total‐cholesterol = 522 mg/dL, LDL‐cholesterol = 434 mg/dL, HDL‐cholesterol = 84 mg/dL, triglycerides = 120 mg/dL, Lp(a) = 13 mg/dL. On December 2015, evolocumab 140 mg sc every 2 weeks was initiated. After a 24‐week treatment, the LDL‐cholesterol levels decreased by an average of 21.2% to 342 ± 22 mg/dL (mean ± SD). On May 2016, LDL‐apheresis (H.E.L.P.system) was started as add‐on therapy. Compared to the average levels obtained during the evolocumab monotherapy period, the LDL‐cholesterol was reduced by 49.4%, thus reaching an inter‐apheresis level (mean ± SD) of 173 ± 37 mg/dL. This report suggests that a combination therapy with evolocumab and lipoprotein‐apheresis may have synergic effects on circulating lipid levels. Its relevance as a highly effective treatment option for hyperlipidemia in HeFH patients warrants further investigation in larger datasets. 相似文献